This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of a A5- containing GABAA receptor agonist (e.g., a A5-containing GABAA receptor positive allosteric modulator) as described herein in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age- Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer' s Disease(AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson' s disease (PD), autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction.Esta invención se refiere a derivados de benzodiazepina, a composiciones que comprenden cantidades terapéuticamente efectivas de esos derivados de benzodiazepina y a métodos para usar esos derivados o composiciones en el tratamiento del deterioro cognitivo asociado con trastornos del sistema nervioso central (SNC). En particular, se refiere al uso de un agonista del receptor GABAA que contiene a5 (por ejemplo, un modulador alostérico positivo para el receptor GABAA que contiene a5) como el descrito en la presente para tratar el deterioro cognitivo asociado con trastornos del sistema nervioso central (SNC) en un sujeto en necesidad o en riesgo, incluyendo, sin limitación, sujetos que tienen o están en riesgo de deterioro cognitivo relacionado con la edad, deterioro cognitivo leve (MCI), MCI amnésico (aMCI), dete
